Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Revenue projections:

Revenue projections for HUM
Revenue projections for HUM

HUM's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 2.003000
forwardPE 14.205882
debtToEquity 74.815000
earningsGrowth 0.000000
revenueGrowth 0.113000
grossMargins 0.145390
operatingMargins -0.017930
trailingEps 9.850000
forwardEps 15.151470

The current ratio for HUM is 2.003, indicating that the company can service its short-term debt using available cash and assets. This suggests HUM has strong liquidity, with more than enough resources to meet its immediate financial commitments.
HUM's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
HUM's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with HUM anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for HUM
Price projections for HUM

Over time, Humana Inc.'s price projections have been consistently revised lower. This suggests analysts are becoming less optimistic about the company's future prospects and are adjusting their forecasts accordingly.

Insider Transactions:

Insider Transactions for HUM
Insider Transactions for HUM


2 separate transactions to buy Humana Inc. were completed, while market price hovered around 205.81500244140625.There were no buy transactions during the given period.The increased selling activity around HUM's current price levels may indicate further downside risk. If this trend continues, the stock's price could face additional declines as selling pressure intensifies.

Recommendation changes over time:

Recommendations trend for HUM
Recommendations trend for HUM


Analysts have been favoring HUM with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning HUM as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.